Clinical trials: Hepatic Neoplasm
Primary Liver Cancer
Clinical Study of VG161 in Subjects with Advanced Primary Liver Cancer
VG161 is a recombinant human-IL12/15/PDL1B oncolytic HSV-1 Injectable. This phase I study will be conducted in HSV-seropositive subjects with advanced primary liver cancer that are refractory to conventional therapies.
- Trial name
- NCT04806464
- Testing
- Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))
- Where
- China
- Volunteers
- 44 people
- Sponsor
- CNBG-Virogin Biotech (Shanghai) Ltd.
Prostate Cancer
A Study to Assess the Effect of Abiraterone Acetate in Male Participants With Mild or Moderate Hepatic Impairment Compared to Matched Control Participants With Normal Hepatic Function
The purpose of this study is to evaluate the safety and pharmacokinetics (study of what the body does to a drug) of 1000 mg oral dose of abiraterone acetate and its major metabolite(s) with mild or moderate hepatic impairment and…
- Trial name
- NCT02001571
- Testing
- Abiraterone acetate
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Cougar Biotechnology, Inc.
Hepatic Encephalopathy
A Retrospective, Open-label, Uncontrolled Cohort Study to Assess the Effectiveness and Safety of Lactulose Retention Enema in the Treatment of Cirrhotic Patients With Grade 3 or 4 (West Haven Criteria) Hepatic Encephalopathy (HE) [The RETRO Study]
This is a retrospective study in adult patients with cirrhosis and grade 3 or 4 HE (West Haven Criteria) to evaluate the effectiveness and safety of lactulose retention enema in the treatment of deep grade HE (West Haven…
- Trial name
- NCT02377947
- Where
- 3 sites in India
- Volunteers
- 50 people
- Sponsor
- Abbott
Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men
A Study to Learn How Different Levels of Decreased Liver Function Influence Blood Levels of Elinzanetant Compared to Normal Liver Function in Male and Female Participants
Researchers are looking for a better way to treat people who have symptoms caused by hormonal changes, like those that happen in women during menopause. These symptoms can include vasomotor symptoms.
- Trial name
- NCT04903821
- Testing
- BAY3427080
- Where
- 2 sites in Germany
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Bayer
Liver Cancer
Safety and Efficacy Evaluation of IM83 CAR-T Cells for Patients With Advanced Liver Tumors
This is a open-label, single center, cohort study to determine the efficacy and safety of IM83 CAR-T cells in patients with advanced Liver Tumors.
- Trial name
- NCT05123209
- Testing
- IM83 CAR-T cells, The second-line treatment of liver cancer
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Beijing Immunochina Medical Science & Technology Co., Ltd.
Hepatocellular Carcinoma, Cholangiocarcinoma
A Phase 1 Study of ZSP1241 in Participants With Advanced Solid Tumors
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics, and determine the maximum tolerated dose of ZSP1241 in participants with hepatocellular carcinoma, cholangiocarcinoma, gastric cancer…
- Conditions
- Hepatocellular Carcinoma, Cholangiocarcinoma, Gastric Cancer, Esophageal Cancer
- Trial name
- NCT03734926
- Testing
- ZSP1241
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Guangdong Zhongsheng Pharmaceutical Co., Ltd.
Hepatocellular Carcinoma, Cholangiocarcinoma
A Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer
This is an open label, multi-center, phase II study of BBI503 administered to adult patients with advanced hepatobiliary cancer who have exhausted all currently approved standard anti-cancer treatment options.
- Trial name
- NCT02232633
- Testing
- BBI503
- Where
- 3 sites in Canada
- Volunteers
- 45 people
- Sponsor
- Sumitomo Pharma America, Inc.
Hepatocellular Carcinoma
Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients
A two part study to determine the maximum tolerated dose and/or recommended phase 2 dose of PDR001 in combination with sorafenib in patients with advanced hepatocellular carcinoma in first line.
- Trial name
- NCT02988440
- Testing
- PDR001, Sorafenib
- Where
- 9 sites in United States, Canada and 6 more
- Volunteers
- 20 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Hepatocellular Carcinoma, Liver Cancer
CS1008- in Combination With Sorafenib Compared to Sorafenib Alone in Subjects With Advanced Liver Cancer
The purpose of this study is to determine the safety and efficacy of CS-1008 in combination with sorafenib to sorafenib alone for treating liver cancer.
- Conditions
- Advanced Hepatocellular Carcinoma, Liver Cancer, Hepatic Cancer, Liver Neoplasms
- Trial name
- NCT01033240
- Testing
- CS-1008 2 mg/kg, Sorafenib, CS-1008 6/2 mg/kg
- Where
- 28 sites in United States, Japan and 2 more
- Volunteers
- 172 people
- Sponsor
- Daiichi Sankyo
Liver Metastases, Colorectal Neoplasms
Phase 3 Trial of Litx™ Plus Chemotherapy vs. Chemotherapy Only Treating Colorectal Cancer Patients With Recurrent Liver Metastases
The purpose of the study is to assess the overall survival and progression free survival of patients treated with Litx™ + chemotherapy versus chemotherapy alone in the treatment of Colorectal Cancer with recurrent liver…
- Conditions
- Liver Metastases, Colorectal Neoplasms, Neoplasm Metastasis, Neoplasm Recurrence, Local
- Trial name
- NCT00440310
- Testing
- Talaporfin sodium, Percutaneous placement of device in liver metastases, Interstitial light emitting diodes
- Where
- 57 sites in Austria, Bosnia and Herzegovina and 11 more
- Volunteers
- 483 people
- Sponsor
- Light Sciences Oncology
Solid Tumors, Hepatocellular Carcinoma (HCC)
A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients With Advanced Solid Tumors, Hepatocellular Carcinoma (HCC), Melanoma, and Pediatric Cancer
In this first-in-human, muticenter, non-randomized, open-label, standard 3+3 dose escalation Phase I study encompasses 5 parts (Part 1-5).
- Conditions
- Solid Tumors, Hepatocellular Carcinoma (HCC), Malignant Melanoma, Pediatric Cancer
- Trial name
- NCT06636435
- Testing
- CBA-1205 Part 1, CBA-1205 Part 2, CBA-1205 Part 3
- Where
- 5 sites in Japan
- Volunteers
- 66 people
- Sponsor
- Chiome Bioscience Inc.
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment
This is a Phase 1b, multicenter, open-label, pharmacokinetic (PK), and safety study of multiple oral doses of oral decitabine and cedazuridine (formerly known as ASTX727) as a fixed-dose combination of decitabine 35 milligrams…
- Trial name
- NCT04953910
- Testing
- ASTX727
- Where
- 22 sites in United States, Armenia and 6 more
- Volunteers
- 27 people
- Sponsor
- Taiho Oncology, Inc.
Hepatocellular Cancer
Survey of Cabozantinib Tablets Used To Treat People With Hepatocellular Carcinoma
This study is a survey in Japan of Cabozantinib tablets used to treat Japanese people with a type of liver cancer called hepatocellular carcinoma.
- Trial name
- NCT05100082
- Testing
- Cabozantinib
- Where
- Japan
- Volunteers
- 263 people
- Sponsor
- Takeda
Hepatocellular Carcinoma
Non-Interventional Registry Study to Evaluate the Effectiveness of TheraSphere® in the Treatment of Hepatocellular Carcinoma (HCC)
The purpose of this registry study is to gather effectiveness, QoL, safety and procedural information on TheraSphere® for the treatment of participants with Hepatocellular Carcinoma (HCC), Intrahepatic Cholangiocarcinoma (iCC)…
- Trial name
- PROACTIF (NCT04069468)
- Testing
- TheraSphere
- Where
- 37 sites in France
- Volunteers
- 1,247 people
- Sponsor
- Boston Scientific Corporation
Hepatocellular Carcinoma
A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
The primary objectives of Cohort A Phase 1b and exploratory expansion are to evaluate the safety and tolerability of TTI-101 orally administered as a single agent to participants with locally advanced or metastatic, and…
- Trial name
- NCT05440708
- Testing
- TTI-101, Pembrolizumab, Atezolizumab
- Where
- 21 sites in United States
- Volunteers
- 193 people
- Sponsor
- Tvardi Therapeutics, Incorporated
Urothelial Carcinoma, Renal Cell Carcinoma
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
This is a multicenter Phase 1b, open-label study to assess safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of cabozantinib taken in combination with atezolizumab in subjects with multiple tumor types…
- Conditions
- Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Castration-resistant Prostate Cancer
- Trial name
- NCT03170960
- Testing
- cabozantinib, atezolizumab
- Where
- 124 sites in United States, Australia and 7 more
- Volunteers
- 914 people
- Sponsor
- Exelixis
Hepatocellular,Carcinoma
Study of Tyroserleutide for Injection in Hepatocellular Carcinoma (HCC) Patients
This is a randomized, double-blinded, placebo-controlled, multi-center Clinical Trial. Patients with no tumor lesions one month after resection of hepatocellular carcinoma will be randomized in a 1:1 ratio to 1 of the 2 treatment…
- Trial name
- NCT01489566
- Testing
- Tyroserleutide for injection ,chemotherapy(mitomycin, and Fluorouracil )
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Shenzhen Kangzhe Pharmaceutical Co., Ltd.
Hepatocellular Carcinoma
Pegylated Recombinant Human Arginase 1 in Combination With Oxaliplatin and Capecitabine for the Treatment of HCC
The propose of the study is to evaluate the maximum tolerated dose (MTD) of Oxaliplatin in combination with pegylated recombinant human arginase 1 (PEG-BCT-100) and Capecitabine and efficacy of this combination regimen (PACOX)in…
- Trial name
- PACOX (NCT02089633)
- Testing
- PACOX
- Where
- Hong Kong
- Volunteers
- 17 people
- Sponsor
- Bio-Cancer Treatment International Limited
Hepatocellular Carcinoma, Liver Metastases
Safety, Tolerability, PK, Anti-Tumor Activity of STP705 in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy
This is an open label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of STP705 administered intratumorally in cholangiocarcinoma, hepatocellular carcinoma…
- Conditions
- Hepatocellular Carcinoma, Liver Metastases, Cholangiocarcinoma
- Trial name
- NCT04676633
- Testing
- STP705
- Where
- 4 sites in United States
- Volunteers
- 5 people
- Sponsor
- Sirnaomics
Hepatocellular Carcinoma
Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCC
This is a prospective, open label, multi-center, interventional study to assess the safety and efficacy of Druvalumab plus Tremelimumab as first-line treatment in Chinese patients with unresectable hepatocellular carcinoma.
- Trial name
- TREMENDOUS (NCT05557838)
- Testing
- Durvalumab, Tremelimumab
- Where
- 29 sites in China
- Volunteers
- 214 people
- Sponsor
- AstraZeneca